Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 cardiovascular outcomes trial in high-risk patients
CTR20234013Phase 3Active
- Sponsor
- 不适用/ 默沙东研发（中国）有限公司
- Start
- Jan 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enlicitide in atherosclerotic disease, hypercholesterolemia, sponsored by 不适用/ 默沙东研发（中国）有限公司. Started Jan 2024; status: active.
02
Drugs
enlicitide
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on CTR20234013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234013.